Journal article · 2023 · Open access
A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China
Frontiers in Pharmacology, 14, 1159906 · Published 11 May 2023 · DOI 10.3389/fphar.2023.1159906
In brief
“A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China” is a 2023 journal article by Yue Dong and 8 co-authors, published in Frontiers in Pharmacology. OpenAlex counts 14 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Pharmacology.
- Citations
- 14
- Most cited in
- 2026 (7)
- Field-weighted impact
- 3.25
- References
- 52
- Authors
- 9
Abstract
Objectives: Patient-reported outcomes (PROs) provide a global perspective of patient health status which plays an enormous role in evaluating clinical efficacy. However, the application of PROs in traditional Chinese medicine (TCM) was still insufficiently studied in mainland China. Methods: This cross-sectional study was performed based on interventional clinical trials of TCM that were conducted in mainland China from 1 January 2010, to 15 July 2022. Data was retrieved from the ClinicalTrials.gov and Chinese Clinical Trial Registry. We included interventional clinical trials of TCM for which the country of the primary sponsors or recruitment settings in mainland China. For each included trial, data including clinical trial phases, study settings, participant’s age, sex, diseases, and the patient-reported outcome measures (PROMs) were extracted. Trials were categorized into four categories according to 1) listed PROs as primary endpoints, 2) listed PROs as secondary endpoints, 3) listed PROs as coprimary outcomes (both primary and secondary endpoints), and 4) did not mention any PROMs. Results: Among a total of 3,797 trials, 680 (17.9%) trials listed PROs as primary endpoints, 692 (18.2%) trials listed PROs as secondary endpoints, and 760 (20.0%) trials listed PROs as coprimary endpoints. Among 675,787 participants included in the registered trials, 448,359 (66.3%) patients’ data were scientifically collected by PRO instruments. Neurological diseases (11.8%), musculoskeletal symptoms (11.5%), mental health conditions (9.1%) were the most common conditions evaluated by PROMs. Disease-specific symptoms related concepts were used most frequently (51.3%), followed by health-related quality of life concepts. Visual analog scale, 36-item Short-Form Health Questionnaire, and TCM symptom score were the most common PROMs in these trials. Conclusion: In this cross-sectional study, the use of PROs increased in the past decades according to clinical trials of TCM conducted in mainland China. Considering that the application of PROs in clinical trials of TCM has some existing issues including uneven distribution and lack of normalized PROs of TCM, further study should be focused on the standardization and normalization of TCM-specific scales.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Dong, Y., Liu, L., Zhang, X., Gong, Y., Yan, S., Li, W., Li, S., Rong, H., & Liu, J. (2023). A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China. Frontiers in Pharmacology, 14, 1159906. https://doi.org/10.3389/fphar.2023.1159906
MLA 9
Dong, Yue, et al. “A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China.” Frontiers in Pharmacology, vol. 14, 2023, p. 1159906. https://doi.org/10.3389/fphar.2023.1159906.
Chicago
Dong, Yue, Lin Liu, Xiaowen Zhang, Yijia Gong, Shiyan Yan, Wěi Li, Shunping Li, Hongguo Rong, and Jianping Liu. 2023. “A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China.” Frontiers in Pharmacology 14: 1159906. https://doi.org/10.3389/fphar.2023.1159906.
Harvard
Dong, Y. et al. (2023) ‘A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China’, Frontiers in Pharmacology, 14, p. 1159906. doi:10.3389/fphar.2023.1159906.
IEEE
Y. Dong et al., “A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China,” Frontiers in Pharmacology, vol. 14, p. 1159906, 2023, doi: 10.3389/fphar.2023.1159906.
BibTeX
@article{dong2023cross,
title = {{A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China}},
author = {Dong, Yue and Liu, Lin and Zhang, Xiaowen and Gong, Yijia and Yan, Shiyan and Li, Wěi and Li, Shunping and Rong, Hongguo and Liu, Jianping},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
pages = {1159906},
doi = {10.3389/fphar.2023.1159906},
url = {https://doi.org/10.3389/fphar.2023.1159906}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 1 | |
| 2025 | 6 | |
| 2026 | 7 |
Its field-weighted citation impact is 3.25: it has been cited 3.25 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Complementary and alternative medicine › Traditional Chinese Medicine Clinical Research
- patient-reported outcomes
- traditional Chinese medicine
- clinical trial endpoints
- health-related quality of life
- TCM symptom score
- SF-36
- visual analogue scale
- neurological disorders
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Dong, Y., Liu, L., Zhang, X., Gong, Y., Yan, S., Li, W., Li, S., Rong, H., & Liu, J. (2023). A cross-sectional study on the application of patient-reported outcome measurements in clinical trials of traditional Chinese medicine in mainland China. Frontiers in Pharmacology, 14, 1159906. https://doi.org/10.3389/fphar.2023.1159906
How many times has this paper been cited?
14 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Pharmacology: sign in and open the PDF from this page.
Who wrote this paper?
Yue Dong, Lin Liu, Xiaowen Zhang, Yijia Gong, Shiyan Yan, Wěi Li, Shunping Li, Hongguo Rong, Jianping Liu.
What is the DOI of this paper?
10.3389/fphar.2023.1159906, permanently at https://doi.org/10.3389/fphar.2023.1159906. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.